These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 2314615)

  • 21. [Natural course and physiopathology of ascites in the cirrhotic patient].
    Bernardi M; Colantoni A; Caraceni P; Sica G; Trevisani F
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():30S-38S. PubMed ID: 9004818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.
    Kalambokis G; Fotopoulos A; Economou M; Pappas K; Tsianos EV
    J Hepatol; 2007 Feb; 46(2):213-21. PubMed ID: 17156883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refractory ascites in cirrhosis: roles of volume expansion and plasma atrial natriuretic factor level elevation.
    Wong F; Tobe S; Legault L; Logan AG; Skorecki K; Blendis LM
    Hepatology; 1993 Sep; 18(3):519-28. PubMed ID: 8395457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenesis of ascites in cirrhosis and portal hypertension.
    Heneghan MA; Harrison PM
    Med Sci Monit; 2000; 6(4):807-16. PubMed ID: 11208415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pathogenesis of ascites formation in liver cirrhosis (author's transl)].
    Arbeiter G; Meyer-Burg J
    Leber Magen Darm; 1974 Oct; 4(6):299-307. PubMed ID: 4373632
    [No Abstract]   [Full Text] [Related]  

  • 26. Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver.
    Jespersen B
    Dan Med Bull; 1997 Apr; 44(2):191-207. PubMed ID: 9151012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The renin-angiotensin-aldosterone system during the extraction, concentration and reinfusion of ascitic fluid in cirrhotic patients].
    Giorcelli V; Fossale PG
    Arch Sci Med (Torino); 1983; 140(3):273-80. PubMed ID: 6675585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluid retention in cirrhosis: pathophysiology and management.
    Kashani A; Landaverde C; Medici V; Rossaro L
    QJM; 2008 Feb; 101(2):71-85. PubMed ID: 18184668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of dipyridamole on kidney function in cirrhosis.
    Llach J; Ginès P; Arroyo V; Salmerón JM; Ginès A; Jiménez W; Gaya J; Rivera F; Rodés J
    Hepatology; 1993 Jan; 17(1):59-64. PubMed ID: 8423042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atrial natriuretic peptide in hepatic cirrhosis: relation to stage of disease, sympathoadrenal system and renin-aldosterone axis.
    Burghardt W; Wernze H; Diehl KL
    Klin Wochenschr; 1986; 64 Suppl 6():103-7. PubMed ID: 2948055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child-Pugh C liver cirrhosis: randomized prospective trial.
    Degoricija V; Zjacic-Rotkvic V; Marout J; Sefer S; Troskot B
    Croat Med J; 2003 Apr; 44(2):178-86. PubMed ID: 12698509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 'Diuretic-resistant' ascites. Observations on pathogenesis.
    Rector WG
    Arch Intern Med; 1986 Aug; 146(8):1597-600. PubMed ID: 3729643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Correction of portal hypertension and renal dysfunction with help of nebivolol and lizinopril in patients with hepatic cirrhosis].
    Fedulenkova LV
    Eksp Klin Gastroenterol; 2009; (5):130-7. PubMed ID: 20201315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Kosta P; Papadimitriou K; Tsianos EV
    J Clin Gastroenterol; 2006 Apr; 40(4):342-6. PubMed ID: 16633107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
    Bansal S; Lindenfeld J; Schrier RW
    Circ Heart Fail; 2009 Jul; 2(4):370-6. PubMed ID: 19808361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.
    Gatta A; Angeli P; Caregaro L; Menon F; Sacerdoti D; Merkel C
    Hepatology; 1991 Aug; 14(2):231-6. PubMed ID: 1860680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased cerebrovascular resistance in cirrhotic patients with ascites.
    Guevara M; Bru C; Ginès P; Fernández-Esparrach G; Sort P; Bataller R; Jiménez W; Arroyo V; Rodés
    Hepatology; 1998 Jul; 28(1):39-44. PubMed ID: 9657094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cirrhotic ascites and the renin-angiotensin system].
    Gonvers JJ; Loup P; Hofstetter JR; Brunner HR
    Schweiz Med Wochenschr; 1980 May; 110(22):869-71. PubMed ID: 6996085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis.
    Genesca J; Gonzalez A; Segura R; Catalan R; Marti R; Varela E; Cadelina G; Martinez M; Lopez-Talavera JC; Esteban R; Groszmann RJ; Guardia J
    Am J Gastroenterol; 1999 Jan; 94(1):169-77. PubMed ID: 9934750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study.
    Abecasis R; Kravetz D; Fassio E; Ameigeiras B; Garcia D; Isla R; Landeira G; Dominguez N; Romero G; Argonz J; Terg R
    Hepatology; 2003 Feb; 37(2):359-65. PubMed ID: 12540786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.